Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Grünwald

Showing results (1-10 of 64) with videos related to

Pageof 7
Sort By:
Der Urologe. Ausg. A|October 24, 2018
[Risk-adapted (immuno)therapy for renal cell carcinoma]V Grünwald
Der Internist|August 21, 2014
[Pharmacotherapy of solid tumors. New hopes and frustrations]V Grünwald, M Rickmann
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 27, 2020
Are we ready to accept intermediate outcome measures in clinical cancer trials?V Grünwald, E Calvo
Aktuelle Urologie|November 12, 2015
[Systemic Treatment of Metastatic Renal Cell Cancer--Back to the Future?]P Ivanyi, V Grünwald
Der Pathologe|May 11, 2019
[Predictive biomarkers in oncologic uropathology]H Reis, T Szarvas, V Grünwald
Der Urologe. Ausg. A|March 3, 2017
[First-line therapy in advanced renal cell carcinoma : A randomized phase II study to examine early switch of tyrosine kinase inhibitors to nivolumab compared to continued tyrosine kinase inhibitor therapy in patients with advanced or metastatic renal cell carcinoma and stable disease after three months of treatment (NIVOSWITCH)-AN 38/15 of the AUO]H Rexer, Th Steiner, V Grünwald
Urologie (Heidelberg, Germany)|March 31, 2022
[Combination hormone therapy for non-metastatic prostate cancer]Carsten Ohlmann, V Grünwald, B Hadaschik
British Journal of Cancer|May 8, 2014
Sunitinib re-challenge in advanced renal-cell carcinomaC Porta, C Paglino, V Grünwald
Der Urologe. Ausg. A|June 9, 2019
[Molecular tumor board-renal cell carcinoma]V Grünwald, C Doehn, P J Goebell
Der Urologe. Ausg. A|April 19, 2020
[Targeted molecular therapy and immunotherapy for prostate cancer]C Grüllich, E Nößner, D Pfister, et al.
Pageof 7

Showing results (1-10 of 64) with videos related to

Sort By:
Pageof 7
Der Urologe. Ausg. A|October 24, 2018
[Risk-adapted (immuno)therapy for renal cell carcinoma]V Grünwald
Der Internist|August 21, 2014
[Pharmacotherapy of solid tumors. New hopes and frustrations]V Grünwald, M Rickmann
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 27, 2020
Are we ready to accept intermediate outcome measures in clinical cancer trials?V Grünwald, E Calvo
Aktuelle Urologie|November 12, 2015
[Systemic Treatment of Metastatic Renal Cell Cancer--Back to the Future?]P Ivanyi, V Grünwald
Der Pathologe|May 11, 2019
[Predictive biomarkers in oncologic uropathology]H Reis, T Szarvas, V Grünwald
Der Urologe. Ausg. A|March 3, 2017
[First-line therapy in advanced renal cell carcinoma : A randomized phase II study to examine early switch of tyrosine kinase inhibitors to nivolumab compared to continued tyrosine kinase inhibitor therapy in patients with advanced or metastatic renal cell carcinoma and stable disease after three months of treatment (NIVOSWITCH)-AN 38/15 of the AUO]H Rexer, Th Steiner, V Grünwald
Urologie (Heidelberg, Germany)|March 31, 2022
[Combination hormone therapy for non-metastatic prostate cancer]Carsten Ohlmann, V Grünwald, B Hadaschik
British Journal of Cancer|May 8, 2014
Sunitinib re-challenge in advanced renal-cell carcinomaC Porta, C Paglino, V Grünwald
Der Urologe. Ausg. A|June 9, 2019
[Molecular tumor board-renal cell carcinoma]V Grünwald, C Doehn, P J Goebell
Der Urologe. Ausg. A|April 19, 2020
[Targeted molecular therapy and immunotherapy for prostate cancer]C Grüllich, E Nößner, D Pfister, et al.
Pageof 7